(S)-9-cyclopentyl-5,7,7-trimethyl-2-(1-p-tolylethylamino)-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one | 1204831-75-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 嘧啶二氮卓类
• 英文名称: (S)-9-cyclopentyl-5,7,7-trimethyl-2-(1-p-tolylethylamino)-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one
• 英文别名: 9-cyclopentyl-5,7,7-trimethyl-2-[[(1S)-1-(4-methylphenyl)ethyl]amino]-8H-pyrimido[4,5-b][1,4]diazepin-6-one
• CAS: 1204831-75-3
• 化学式: C₂₄H₃₃N₅O
• 分子量: 407.559
• InChiKey: UYSRVVIORGEWFX-KRWDZBQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  61.4
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINE KINASE
  申请人：VERTEX PHARMA

  公开号：WO2010008454A1

  公开（公告）日：2010-01-21

  In one aspect, the invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof. In another aspect, the invention provides methods for treatment of diseases or disorders mediated by a protein kinase, comprising administering a therapeutically effective amount of a compound of this invention.

  在一个方面，该发明提供了式（I）的化合物或其药学上可接受的盐。在另一个方面，该发明提供了治疗由蛋白激酶介导的疾病或障碍的方法，包括给予本发明化合物的治疗有效量。
• [EN] METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS<br/>[FR] PROCÉDÉS DE PRÉPARATION DE DÉRIVÉS DE PYRIMIDINE UTILES COMME INHIBITEURS DE LA PROTÉINE KINASE
  申请人：VERTEX PHARMA

  公开号：WO2011036566A1

  公开（公告）日：2011-03-31

  A method of preparing a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and claims, comprises the steps of: a) reacting a compound represented by Structural Formula (A) with FTNR1R7 under suitable conditions to form a compound represented by Structural Formula (B); and b) i) when R12 is -NO2, and R11 is -OR14: 1) cyclizing the compound represented by Structural Formula (B) under suitable cyclisation conditions to form a compound represented by Structural Formula (II); and 2) optionally reacting the compound represented by Structural Formula (II) with R9-LG2, wherein LG2 is a suitable leaving group, to form the compound represented by Structural Formula (I), wherein R8 is R9; or ii) when R12 is halogen, and R11 is -NHR13: 1) cyclizing the compound represented by Structural Formula (B) under suitable cyclisation conditions to form the compound represented by Structural Formula (I); and 2) optionally, when R13 is - H, reacting the compound produced from step b), ii), 1) with R9-LG2, wherein LG2 is a suitable leaving group, to form the compound represented by Structural Formula (I) wherein R8 is R9.

  一种制备化合物结构式（I）或其药学上可接受的盐的方法，其中结构式（I）中的变量如说明书和权利要求中所述，包括以下步骤：a）在适当的条件下，将化合物结构式（A）与FTNR1R7反应，形成化合物结构式（B）；和b）i）当R12为-N02，而R11为-OR14时：1）在适当的环化条件下，使化合物结构式（B）环化形成化合物结构式（II）；和2）可选择地将化合物结构式（II）与R9-LG2反应，其中LG2是适当的离去基团，形成化合物结构式（I），其中R8为R9；或ii）当R12为卤素，而R11为-NHR13时：1）在适当的环化条件下，使化合物结构式（B）环化形成化合物结构式（I）；和2）可选择地，当R13为-H时，将从步骤b）ii）1）产生的化合物与R9-LG2反应，其中LG2是适当的离去基团，形成化合物结构式（I），其中R8为R9。
• METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS
  申请人：Charrier Jean-Damien

  公开号：US20120271045A1

  公开（公告）日：2012-10-25

  A method of preparing a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and claims. Additionally, the present invention relates to compounds of Structural Formula (I), which are useful as inhibitors of protein kinase.

  一种制备结构式（I）所代表的化合物或其药学上可接受的盐的方法，其中结构式（I）的变量如规范和权利要求所述。此外，本发明涉及结构式（I）的化合物，其作为蛋白激酶抑制剂是有用的。
• PROTEIN KINASE INHIBITORS
  申请人：Charrier Jean-Damien

  公开号：US20120322793A1

  公开（公告）日：2012-12-20

  In one aspect, the invention provides compounds of Formula I or pharmaceutically acceptable salts thereof. In another aspect, the invention provides methods for treatment of diseases or disorders mediated by a protein kinase, comprising administering a therapeutically effective amount of a compound of this invention.

  在一个方面，本发明提供了公式I的化合物或其药学上可接受的盐。在另一个方面，本发明提供了治疗由蛋白激酶介导的疾病或紊乱的方法，包括给予本发明化合物的治疗有效量。
• US8278297B2
  申请人：——

  公开号：US8278297B2

  公开（公告）日：2012-10-02